0 false false false false false false false true false false true false false false false false false No description of principal activity 2024-01-09 Sage Accounts Production Advanced 2023 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 15401074 2024-01-09 2024-09-30 15401074 2024-09-30 15401074 2024-01-08 15401074 bus:Director1 2024-01-09 2024-09-30 15401074 core:ShareCapital 2024-09-30 15401074 bus:SmallEntities 2024-01-09 2024-09-30 15401074 bus:AuditExempt-NoAccountantsReport 2024-01-09 2024-09-30 15401074 bus:SmallCompaniesRegimeForAccounts 2024-01-09 2024-09-30 15401074 bus:PrivateLimitedCompanyLtd 2024-01-09 2024-09-30 15401074 bus:FullAccounts 2024-01-09 2024-09-30
COMPANY REGISTRATION NUMBER: 15401074

C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED

FILLETED UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD ENDED

30 September 2024

C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED

STATEMENT OF FINANCIAL POSITION

30 September 2024

| 30 Sep 24
Note | £

CURRENT ASSETS

Debtors | 4 | 100
| -----
NET CURRENT ASSETS | 100
| -----
TOTAL ASSETS LESS CURRENT LIABILITIES | 100
| -----

CAPITAL AND RESERVES

Called up share capital | 100
| -----
SHAREHOLDER FUNDS | 100
| -----

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
The company did not trade during the period and has not made either a profit or loss.
For the period ending 30 September 2024 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.
Directors' responsibilities:
- The member has not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 20 June 2025 , and are signed on behalf of the board by:

Professor N S Scrutton
Director

Company registration number: 15401074

C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED

NOTES TO THE FINANCIAL STATEMENTS

PERIOD FROM 9 JANUARY 2024 TO 30 SEPTEMBER 2024
1. GENERAL INFORMATION
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 20 Mannin Way, Lancaster Business Park, Caton Road, Lancaster, LA1 3SW.
2. STATEMENT OF COMPLIANCE
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. ACCOUNTING POLICIES
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Income statement
The company is dormant as defined by section 1169 of the Companies Act 2006. The company received no income and incurred no expenditure during the current period.
4. DEBTORS

| 30 Sep 24
| £

Other debtors | 100
| -----